+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Anesthesia Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4591601
  • Report
  • April 2019
  • Region: Europe
  • 75 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Abbott
  • AbbVie Inc.
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter
  • F. Hoffmann-La Roche AG
  • MORE
Market Overview

The European anesthesia drugs market is expected to witness a CAGR of 2.4% during the forecast period. Certain factors that are driving the market growth include an increasing number of surgeries, new approvals of anesthetic drugs, and reduction in the cost of newly invented drugs.

According to a National Health Service (NHS), in 2013-2014, there were an estimated 4.7 million surgical admissions in England, among all the surgeries, general surgeries, trauma, and orthopedic procedures were the most common ones. The number of surgeries being performed is rising every year. The overall increase in the number of surgeries performed has a substantial impact on the anesthetics market, as they are used in all surgical procedures to reduce the pain during surgery. Along with rising surgeries, factors, such as new anesthetic drugs are also driving the market.

However, general anesthetic drugs cause several side-effects, including nausea, vomiting, dry mouth, sore throat, shivering, muscle aches, disorientation, itching, sleepiness, and mild hoarseness. More serious complications of the drug include delirium, cognitive dysfunction, and malignant hyperthermia. General anesthetic drugs can cause physiological changes, such as blood pressure variations which require a trained anesthesiologist to monitor the patient’s blood pressure levels continuously and might have to provide blood pressure medications. Carelessness or lack of knowledge of the anesthesiologist could pose as a potential risk. Hence, the side-effects of general anesthesia and the patient’s reluctance toward using it are restraining the segment growth. The other factors, such as lack of skilled anesthetics and regulatory issues are restraining the market growth.

Scope of the Report

Anesthesia is a drug that causes a reversible loss of sensation. There are several types of anesthetic drugs available in the market, such as general anesthesia, spinal anesthesia, IV regional anesthesia, local anesthesia, peripheral nerve block, and saddle block or caudal anesthesia.

Key Market Trends

Propofol Sub-segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment

Propofol is a drug that has been used for a long time for various surgical procedures requiring anesthesia. Teva Pharmaceuticals had stopped manufacturing propofol for a particular time, however, the drug returned to the market in 2013. Hospira is another major player in the propofol sub-segment. In 2015, Pfizer acquired Hospira and created a leading global established pharmaceutical (GEP) business. Some of the companies who manufacture propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi. The drug is always in demand in the market for utilization in different surgeries and is expected to witness a rapid growth in the coming years.

Competitive Landscape

The European anesthesia drugs market is highly competitive and consists of a few major players. In terms of market share, a few of the major players currently dominate the market. Companies like Abbott, AbbVie Inc., AstraZeneca, B. Braun Melsungen AG, Baxter, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, Fresenius SE & Co. KGaA, and Hospira, among others, hold the substantial market share in the European anesthesia drugs market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • AbbVie Inc.
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter
  • F. Hoffmann-La Roche AG
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 New Approvals of Anesthetic Drugs
4.2.3 Reduction in the Cost of Newly Invented Drugs
4.3 Market Restraints
4.3.1 Side Effects of General Anesthetics
4.3.2 Lack of Skilled-Anesthetics
4.3.3 Regulatory Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Drug Type
5.1.1 General Anesthesia Drugs
5.1.1.1 Propofol
5.1.1.2 Sevoflurane
5.1.1.3 Desflurane
5.1.1.4 Dexmedetomidine
5.1.1.5 Remifentanil
5.1.1.6 Midazolam
5.1.1.7 Other General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
5.1.2.1 Bupivacaine
5.1.2.2 Ropivacaine
5.1.2.3 Lidocaine
5.1.2.4 Chloroprocaine
5.1.2.5 Articaine
5.1.2.6 Benzocaine
5.1.2.7 Other Local Anesthesia Drugs
5.2 Route of Administration
5.2.1 Inhalation
5.2.2 Injection
5.2.3 Other Routes of Administration
5.3 Application
5.3.1 General Surgeries
5.3.2 Plastic Surgery
5.3.3 Cosmetic Surgeries
5.3.4 Dental Surgeries
5.3.5 Other Applications
5.4 Geography
5.4.1 Europe
5.4.1.1 United KIngdom
5.4.1.2 Germany
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 AbbVie Inc.
6.1.3 AstraZeneca
6.1.4 B. Braun Melsungen AG
6.1.5 Baxter
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Fresenius SE & Co. KGaA
6.1.9 Hospira

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott
  • AbbVie Inc.
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche AG
  • Fresenius SE & Co. KGaA
  • Hospira
Note: Product cover images may vary from those shown
Adroll
adroll